Here’s what you need to know about Sinopharm’s COVID-19 vaccine

Trending Now Here’s what you need to know about Sinopharm’s COVID-19 vaccine

May 04, 2021 1:00 pm
Viewed 46 times

MANILA, Philippines Notwithstanding its pending application for emergency use authorization (EUA) from the countrys Food and Drug Administration (FDA),President Rodrigo Duterte gave his ultimate seal of approval for the Chinese coronavirus vaccine produced by Sinopharm when he had himself inoculated Monday night.

A video of Duterte getting his vaccine of choice was released by his longtime aide, Senator Christopher Bong Go prior to the Presidents public address Monday night. In the video, no less than Health Secretary Francisco Duque III administered the vaccine on the President on the basis of a compassionate special permit (CSP).

Dutertes inoculation was contrary to an earlier statement by Malacaang which stated that the President will wait for the China-based pharmaceutical group to secure an EUA before receiving its jab.

So far, the regulator has granted an EUA to COVID-19 vaccines developed and produced by six pharmaceutical groups including Pfizer-BioNTech, AstraZeneca, Sinovac, Gamaleya Research Institute, Johnson & Johnson, and Bharat Biotech.

Presidential spokesperson Harry Roque previously said that the Palace will no longer seek inclusion of the President in the compassionate use license of Sinopharm issued to the Presidential Security Group (PSG) by the FDA.

Chinese state-owned company Sinopharm started putting the inactivated coronavirus vaccine created by the Beijing Institute of Biological Products into clinical trials last year.

The company has also tested a similar vaccine developed by the Wuhan Institute of Biological Products.

Below is the side-by-side comparison of Beijing-Sinopharms BBIP-CorV vaccine and Wuhan-Sinopharm vaccine based on data from the COVID-19 vaccine tracker by the Vaccine Centre at the London School of Hygiene & Tropical Medicine.

Similar to Sinovacs CoronaVac and Bharat Biotechs Covaxin, the vaccines developed by Sinopharm in Beijing and Wuhan also use inactivated virus to make antibodies against SARS-CoV-2 the virus that causes COVID-19.

According to the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4), these inactivated pathogens are grown in culture and killed in laboratories to reduce their virulence or the ability to infect and cause damage to a host.

Since the viruses in the vaccine are already dead, they can be injected into a person without causing COVID-19.

Inactivated viruses, which do not have the ability to replicate themselves, are also being used in polio and influenza vaccines. It also stands as the bases for vaccines against other diseases such as rabies and hepatitis A.

Sinopharm reported in December last year that the vaccine developed by its Beijing unit was 79.34 percent effective at protecting people from COVID-19.

According to the company, this is based on an interim analysis of the vaccines Phase 3 clinical trials. It is, however, lower than the 86 percent efficacy rate earlier announced by UAE based on preliminary data from trials there.

On the other hand, Sinopharms Wuhan unit in February said that its vaccine had shown an efficacy rate of 72.51 percent against COVID-19 based on an interim analysis of its Phase 3 clinical trials.

Data from the World Health Organizations (WHO) COVID-19 vaccine landscape and tracker as of April 30 showed that the vaccine by Sinopharms Beijing unit is currently at Phase 4 clinical trial while the vaccine produced by the Wuhan unit is still at Phase 3.

There are four trials registered for the Phase 3 clinical trials of Sinopharm-Beijings BBIBP-CorV. These trials are located in Bahrain, Egypt, Jordan, UAE, Peru, and Argentina.

Meanwhile, data from a website maintained by the US National Library of Medicine (NLM) at the National Institutes of Health (NIH) bared that the Phase 4 trial for BBIBP-CorV has not yet started.

The Phase 3 trials for Wuhans vaccine, on the other hand, are likewise located in Bahrain, Egypt, Jordan, UAE, Peru, including Morocco.

In terms of vaccine approval, Beijings BBIBP-CorV has been so far approved for full or emergency use in at least 40 countries.

The Chinese government in February announced the approval of Wuhans COVID-19 for vaccine use while UAE has issued an EUA for the vaccine.

During a televised speech last December 26, Duterte said several military personnel were already inoculated with a vaccine against COVID-19 developed by Chinas Sinopharm.

Both Interior and Local Government Secretary Eduardo Ao and AFP spokesperson Maj. Gen. Edgard Arevalo then confirmed that that the Presidential Security Group (PSG) has received jabs of the Sinopharm vaccine.

Commander Brig. Gen. Jesus Durante III further said that some of the PSGs personnel have already been vaccinated against COVID-19 as early as September, despite the non-issuance of an EUA or compassionate use authorization.

Amid fierce criticisms from lawmakers and several groups, Malacaang explained there was no violation of the anti-graft law when PSG received the vaccines because these were only tokens and no public funds were used for it.

In December, 2020,Justice Secretary Menardo Guevarra said he had ordered an investigation into the use of Sinopharm to inoculate presidential guards for COVID-19 as it might have violated several laws, contrary to administration officials claims that it was not unlawful.

Guevarra said he had directed the National Bureau of Investigation to look into the use of the vaccine developed by the Chinese pharmaceutical company Sinopharm and how it was brought into the Philippines, and unauthorized inoculation on military troops.

In January, 2021, the AFP called off its own investigation on PSGs use of unauthorized Chinese coronavirus vaccines.

That same month, the Senate said it will proceed with an inquiry into the governments vaccination program despite Dutertes threat of a crisis if the senators insist on questioning the PSGs inoculation with Sinopharm.

In February, FDA issued a compassionate use license for 10,000 doses of China-based Sinopharms COVID-19 vaccine.

The compassionate use license allowsthe PSG to get access to unregistered vaccines sans an EUA from the FDA, which is required before a vaccine can be administered legally in the country.

Meanwhile, both the FDA and the Department of Health (DOH) vowed to probe the vaccination of President Rodrigo Dutertes former special envoy to China Mon Tulfo using smuggled vaccines from Sinopharm.

Tulfo had admitted to using the vaccine, further saying that he would quit his post should he be appointed by Sinopharm as its distributor in the country.

Last month, vaccine czar Carlito Galvez Jr. said that UAE is planning to donate 500,000 doses of the Sinopharm vaccine to the Philippines.

As to what would happen to these government investigations on the use of Sinopharm is unknown after Dutertes endorsement of the locally unregistered vaccine.